NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Authors Pearson, Steven D., author Remove constraint Authors: Pearson, Steven D., author

Search Results

1. Using comparative effectiveness research to pay equally for equivalent outcomes: an evaluation of a multi-stakeholder effort focused on prostate cancer treatments

2. Diagnostic tests for Alzheimer's disease: generating and evaluating evidence to inform insurance coverage policy

3. The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection: a technology assessment : final report

4. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks : final report

5. CardioMEMS (tm) HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto (tm), Novartis AG) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks : final report

6. Integrating behavioral health into primary care: a technology assessment : final report

7. Indication-specific pricing of pharmaceuticals in the United States health care system: a report from the 2015 ICER Membership Policy Summit

8. Palliative care in the outpatient setting: a comparative effectiveness report : final report

9. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: comparative clinical effectiveness and value : evidence report

10. Obeticholic acid for the treatment of primary biliary cholangitis: comparative clinical effectiveness, value, and value-based price benchmarks : evidence report

11. Mepolizumab (Nucala??, GlaxoSmithKline plc.) for the treatment of severe asthma with eosinophilia: effectiveness, value, and value-based price benchmarks : final report

12. Insulin degludec (Tresiba??, Novo Nordisk A/S) for the treatment of diabetes: effectiveness, value, and value-based price benchmarks : final report

13. Controversies in migraine management: a technology assessment : final report

14. Controversies in obesity management: a technology assessment : final report

15. Medications for obesity management: effectiveness and value : final evidence report

16. AMX0035 and oral edaravone for amyotrophic lateral sclerosis: final evidence report

17. Betibeglogene autotemcel for beta thalassemia: effectiveness and value : final evidence report

18. Special assessment of outpatient treatments for COVID-19: final evidence report and meeting summary

19. Novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects: revised evidence report

20. Tirzepatide for type 2 diabetes: final report

21. Digital health technologies as an adjunct to medication assisted therapy for opioid use disorder: final evidence report and meeting summary

22. Supervised injection facilities and other supervised consumption sites: effectiveness and value : final report

23. Unsupported price increase report: 2020 assessment

24. Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value : final report

25. Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value : final report

26. Alirocumab for treatment of high cholesterol: effectiveness and value : new evidence update

27. Oral immunotherapy and Viaskin Peanut for peanut allergy: effectiveness and value : final evidence report

28. Mavacamten for hypertrophic cardiomyopathy: effectiveness and value : final evidence report and meeting summary

29. Tezepelumab for severe asthma: final report

30. Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value : final report

32. Aducanumab for Alzheimer’s disease: effectiveness and value

33. Targeted immune modulators for ulcerative colitis: effectiveness and value : final evidence report and meeting summary

34. Strengthening the accelerated approval pathway: an analysis of potential policy reforms and their impact on uncertainty, access, innovation, and costs

35. Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: effectiveness and value

37. Belimumab and voclosporin for lupus nephritis: effectiveness and value : final report

38. Treatments for anemia in chronic kidney disease: effectiveness and value : final evidence report

39. Gene therapies for sickle cell disease: final evidence report

40. Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH): final evidence report

41. Lecanemab for early Alzheimer’s disease: final evidence report

42. JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value : final evidence report

43. Tezepelumab for severe asthma: final report

44. Fezolinetant for moderate to severe vasomotor symptoms associated with menopause: effectiveness and value : final evidence report

45. Gene therapy for hemophilia B and an update on gene therapy for hemophilia A: effectiveness and value : final evidence report

46. Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update

47. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma: final report